# Mike Novotny

> Mike Novotny is the founder and CEO of Medrio, a San Francisco-based eClinical SaaS company he started in his apartment in 2005. Over 15 years he bootstrapped Medrio into a nine-figure company that has helped customers win regulatory approvals for more than 100 treatments. After a sabbatical researching organizational development, he returned as CEO in 2025, betting that AI will reshape clinical trial data management. Before Medrio, he was CEO of Telosa, President of Ninaza, a UN research associate, and managed the fraud database at Visa. He holds degrees from Stanford, PUC Chile, and Columbia.

- **Role:** Founder & CEO at Medrio
- **Organizations:** Medrio, Telosa, Ninaza, Visa, United Nations
- **Nationality:** American
- **Education:** BA, Stanford University, MA, PUC University (Pontificia Universidad Católica de Chile), MBA, Columbia University
- **Known for:** Founded Medrio in 2005 and bootstrapped it to nine-figure valuation without institutional funding for 12 years, Helped customers gain regulatory approvals for more than 100 medical treatments, Oversaw more than 2,000 clinical trials run on Medrio platform

## Career timeline

- **Early career** — Research Associate, United Nations
- **Early career** — Manager, Fraud Database, Visa
- **Pre-2005** — President, Ninaza (EDC software company)
- **Pre-2005** — CEO, Telosa
- **2005** — Founded Medrio in his San Francisco apartment
- **2005-2020** — Served as Founder & CEO of Medrio for 15 years, growing it into a nine-figure company
- **2017** — Medrio raises $30M from Questa Capital - its first institutional funding after 12 years of self-funding
- **2020** — Stepped down as CEO after 15 years; transitioned to Founder/Board Member; took sabbatical researching organizational development
- **2025** — Returned as CEO of Medrio, citing AI acceleration as key driver for return

## Achievements

- Founded Medrio in 2005 and bootstrapped it to nine-figure valuation without institutional funding for 12 years
- Helped customers gain regulatory approvals for more than 100 medical treatments
- Oversaw more than 2,000 clinical trials run on Medrio platform
- Led $30M Series A from Questa Capital in 2017 - Medrio's first ever institutional raise
- Built Medrio to $43M annual revenue with approximately 180 employees
- Positioned Medrio as a leading global cloud-based eClinical software platform
- Pioneered the 'Easy Button' approach to EDC software, differentiating from complexity-focused competitors

## Latest updates

- **2025-01** — Returned as CEO of Medrio after sabbatical, citing AI's transformative impact on clinical research as the reason for his return
- **2025-01** — Posted on LinkedIn: 'It's great to be back as CEO of Medrio! I'm a product manager by training who loves building great eClinical tools.'
- **2025-01** — Posted on LinkedIn: 'I'm back in the saddle as CEO because AI accelerates everything'

## Links

- Website: https://medrio.com
- LinkedIn: http://www.linkedin.com/in/michaelnovotny
- Twitter/X: https://twitter.com/medrio
- Facebook: https://facebook.com/MEDRIOeClinical/

---

Profile page: https://yespress.io/mike-novotny
Published by YesPress — https://yespress.io
Last updated: 2026-05-12